JP2021004215A - Mc1r発現抑制剤 - Google Patents
Mc1r発現抑制剤 Download PDFInfo
- Publication number
- JP2021004215A JP2021004215A JP2019119567A JP2019119567A JP2021004215A JP 2021004215 A JP2021004215 A JP 2021004215A JP 2019119567 A JP2019119567 A JP 2019119567A JP 2019119567 A JP2019119567 A JP 2019119567A JP 2021004215 A JP2021004215 A JP 2021004215A
- Authority
- JP
- Japan
- Prior art keywords
- mc1r
- ascorbic acid
- expression inhibitor
- expression
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 47
- 239000003112 inhibitor Substances 0.000 title claims abstract description 29
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 title claims description 45
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 title claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 57
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 40
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 34
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 17
- 208000003351 Melanosis Diseases 0.000 claims description 13
- 206010014970 Ephelides Diseases 0.000 claims description 10
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical group OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 10
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 abstract description 45
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 abstract 5
- 210000003491 skin Anatomy 0.000 description 20
- 150000000996 L-ascorbic acids Chemical class 0.000 description 11
- -1 ascorbic acid monophosphate ester Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002087 whitening effect Effects 0.000 description 5
- 206010040829 Skin discolouration Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 108700039887 Essential Genes Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 231100000960 LabCyte EPI-MODEL 24 Toxicity 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SWGARUWMPUMTGP-SHRWCKKSSA-N (2R)-2-[(1S)-1,2-dihydroxy-3-oxobutyl]-3,4-dihydroxy-2H-furan-5-one Chemical compound C(C)(=O)C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O SWGARUWMPUMTGP-SHRWCKKSSA-N 0.000 description 1
- ZSJPUFLDBIJDAT-QFBIRUJASA-N (2R)-2-[(1S)-1,2-dihydroxyhexyl]-3,4-dihydroxy-2H-furan-5-one Chemical compound C(CCC)C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O ZSJPUFLDBIJDAT-QFBIRUJASA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 101150015860 MC1R gene Proteins 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 108010000410 MSH receptor Proteins 0.000 description 1
- 102000012539 Melanocyte-stimulating hormone receptors Human genes 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
項1. アスコルビン酸、その誘導体、及びそれらの塩よりなる群から選択される少なくとも1種を有効成分として含む、MC1R発現抑制剤。
項2. 前記有効成分がアスコルビン酸2−グルコシドである、項1に記載のMC1R発現抑制剤。
項3. 雀卵斑の憎悪予防又は改善のために使用される、項1又は2に記載のMC1R発現抑制剤。
項4. 皮膚外用剤である、項1〜3のいずれかに記載のMC1R発現抑制剤。
本発明のMCR1発現抑制剤で使用する有効成分は、アスコルビン酸、その誘導体、及びそれらの塩よりなる群から選択される少なくとも1種(以下、「アスコルビン酸類」と表記することもある)である。
本発明のMC1R発現抑制剤は、アスコルビン酸類の他に、必要に応じて、他の機能性成分を含有していてもよい。このような機能性成分としては、例えば、抗ヒスタミン剤、局所麻酔剤、抗炎症剤、皮膚保護剤、血行促進成分、清涼化剤、アスコルビン酸類以外のビタミン類、ムコ多糖類等が挙げられる。
本発明のMC1R発現抑制剤は、皮膚外用剤、内服剤等のいずれの剤型であってもよいが、MC1R発現抑制作用を効果的に発揮させるという観点から、好ましくは皮膚外用剤が挙げられる。
本発明のMC1R発現抑制剤は、表皮細胞におけるMC1Rの発現を抑制する用途に使用される。表皮細胞におけるMC1Rの亢進は、特に、雀卵斑等の遺伝性の色素異常症に関与しているので、本発明のMC1R発現抑制剤は、そばかす等の遺伝性の色素異常症の憎悪予防又は改善に好適に使用される。
ヒト三次元培養表皮モデル(「LabCyte EPI-MODEL24」、株式会社ジャパン・ティッシュ・エンジニアリング)を使用して、L−アスコルビン酸2−グルコシドがMC1R発現に及ぼす影響について検討した。
Claims (4)
- アスコルビン酸、その誘導体、及びそれらの塩よりなる群から選択される少なくとも1種を有効成分として含む、MC1R発現抑制剤。
- 前記有効成分がアスコルビン酸2−グルコシドである、請求項1に記載のMC1R発現抑制剤。
- 雀卵斑の予防又は改善のために使用される、請求項1又は2に記載のMC1R発現抑制剤。
- 皮膚外用剤である、請求項1〜3のいずれかに記載のMC1R発現抑制剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019119567A JP2021004215A (ja) | 2019-06-27 | 2019-06-27 | Mc1r発現抑制剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019119567A JP2021004215A (ja) | 2019-06-27 | 2019-06-27 | Mc1r発現抑制剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021004215A true JP2021004215A (ja) | 2021-01-14 |
Family
ID=74099206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019119567A Pending JP2021004215A (ja) | 2019-06-27 | 2019-06-27 | Mc1r発現抑制剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2021004215A (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193504A (ja) * | 2004-09-24 | 2006-07-27 | Shiseido Co Ltd | 美白剤 |
JP2010515768A (ja) * | 2007-01-16 | 2010-05-13 | ラボラトワール マヨリ スパンドレ | メラニン形成を阻害する化合物の組合せならびに化粧品および皮膚用品におけるそれらの使用 |
JP2016084330A (ja) * | 2014-10-28 | 2016-05-19 | 富士フイルム株式会社 | 日焼け止め化粧料 |
-
2019
- 2019-06-27 JP JP2019119567A patent/JP2021004215A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006193504A (ja) * | 2004-09-24 | 2006-07-27 | Shiseido Co Ltd | 美白剤 |
JP2010515768A (ja) * | 2007-01-16 | 2010-05-13 | ラボラトワール マヨリ スパンドレ | メラニン形成を阻害する化合物の組合せならびに化粧品および皮膚用品におけるそれらの使用 |
JP2016084330A (ja) * | 2014-10-28 | 2016-05-19 | 富士フイルム株式会社 | 日焼け止め化粧料 |
Non-Patent Citations (3)
Title |
---|
AQUACULTURE, vol. 443, JPN6023017786, 2015, pages 65 - 76, ISSN: 0005051364 * |
HUMAN MOLECULAR GENETICS, vol. 10, no. 16, JPN7023001702, 2001, pages 1701 - 1708, ISSN: 0005051365 * |
PIGMENT CELL MELANOMA RES., vol. 27, JPN6023017787, 2014, pages 339 - 350, ISSN: 0005051366 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI480057B (zh) | 咖啡酸醯胺衍生物之應用 | |
JP3049593B2 (ja) | 育毛・養毛剤 | |
JP2011130725A (ja) | Lnaオリゴヌクレオチドとそれを含有する化粧品 | |
WO2005044205A1 (ja) | 毛髪の太毛化の方法及び組成物 | |
ES2904592T3 (es) | Agente antienvejecimiento y composición antienvejecimiento para la piel | |
JP5787246B2 (ja) | 角化細胞遊走・増殖促進剤を含む、創傷治癒剤および褥瘡(床ずれ)治療薬 | |
JP2006290873A (ja) | アクアポリン発現促進剤 | |
EP2585077B1 (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
JP2021004215A (ja) | Mc1r発現抑制剤 | |
JP2019529462A (ja) | Tnfrsf 14抑制物質を含む皮膚美白用組成物及びtnfrsf 14抑制物質のスクリーニング方法 | |
KR20150025984A (ko) | 21-o-안젤로일티아사포제놀 e3을 포함하는 발모 또는 육모 촉진용 조성물 | |
KR102083405B1 (ko) | 스티풀레아노사이드 r1을 유효성분으로 함유하는 피부 노화 방지 및 주름 개선용 조성물 | |
JP4368072B2 (ja) | 皮膚外用剤 | |
KR102292961B1 (ko) | microRNA-2478을 포함하는 멜라닌 생성 억제용 조성물 | |
JPH07242542A (ja) | 化粧料 | |
JP2017014205A (ja) | トリプターゼ阻害剤組成物 | |
TWI734058B (zh) | 柳葉蠟梅萃取物用於延緩皮膚細胞老化的用途 | |
JP7433625B2 (ja) | Mmp発現抑制剤 | |
JP2002145802A (ja) | ニキビ用皮膚外用剤 | |
EP3363426B1 (en) | Composition for skin whitening containing amorphigeni as active ingredient | |
JP6804352B2 (ja) | コラゲナーゼmmp1及び3の産生抑制剤 | |
KR101984276B1 (ko) | 베르베린 하이드로클로라이드를 유효성분으로 포함하는 체모성장 저해용 조성물 | |
JP6425400B2 (ja) | 皮膚表面に接触させて使用される組成物 | |
KR101511446B1 (ko) | 우스닉산을 유효성분으로 포함하는 체모성장 저해용 조성물 | |
KR20160093420A (ko) | 베르베린 또는 이의 약학적으로 허용 가능한 염을 포함하는 다크서클 개선용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220527 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240205 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240402 |